GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Discover a study validating a disease-specific quality-of-life tool for hidradenitis suppurativa, confirming its reliability, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics’s ...

The dermatology team at Zulekha Hospital is trained in the latest biological therapies ...

Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

A significant burden of neuropsychiatric comorbidities exists among patients with PPD and various psychophysiological disorders.